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ABSTRACT 
Aim & Objective: The study was planned to evaluate the effectiveness of pharmaceutical care on the control of medical parameters, 
such as Fasting plasma glucose, Glycosylated hemoglobin (HbA1c) and BMI also to evaluate drug therapy problems in patients with 
type 2 diabetes mellitus. Setting: the study was conducted at SBHGM College, Civil Hospital in Dhule MS.  
Research design and Methods: A prospective, Open label  and randomized control study was conducted with 200 type 2 diabetes 
patients with glycosylated haemoglobin of higher than 7.5%, they were divided into two groups: (I) control group without 
pharmaceutical care program (n=100), and (II) pharmaceutical care program (intervention) group (n=100).They were monitored for 
3 consecutive visits. Patients in the control group received usual medical care, but patients in the intervention group received both 
standard medical care and pharmaceutical care.  
Results: At the end of the study, a statistically significant fall was observed in the glycemic levels, BMI of patients in the 
intervention group as a small reduction, which is statistically not significant, was observed in the control group. Additionally, the 
follow-up of the intervention group by a pharmacist contributed to the resolution of 118 drug therapy problems identified.  
Conclusion: pharmaceutical care program provide by pharmacist to patients with type 2 diabetes mellitus can give up measurable 
improvements in the glycemic control, BMI & resolute of drug therapy problems and improvements in the adherence to antidiabetic 
medication.                                            
Keywords: Type 2 Diabetes mellitus, Pharmaceutical care program, and Fasting plasma glucose, Glycosylated hemoglobin (HbA1c) 
and Body mass index (BMI).                                                                        
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INTRODUCTION 
Diabetes mellitus is a chronic disease condition 
characterized by hyperglycemia, that is associated with 
high morbidity and mortality from its complications 
which if uncontrolled leads to various short terms and 
long-term complications. Diabetes mellitus with its 
associated complications such as cardiovascular 
diseases, retinopathy, nephropathy, and neuropathy is a 
serious health problem 
1,2
. Type 2 Diabetes mellitus 
account for 90-95% of those with Diabetes mellitus The 
prevalence rate of Type 2 Diabetes mellitus is high in 
India and is expected to rise. This rise is due to low 
literacy rate, lack of public awareness, lack of advanced 
healthcare facilities and sedentary lifestyle.
3,4
 in this 
study also the high prevalence rate of type2 diabetes in 
Dhule Maharashtra due to low literacy rate, lack of 
public awareness, lack of advanced healthcare facilities 
and inactive lifestyle. The contribution of pharmacists in 
diabetes management is so far not documented in India.
 
5
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The complication danger is directly related to high 
blood glucose levels.
3,5
 however, as most patients with 
type 2 diabetes mellitus have a combination of risk 
factors together with obesity, hypertension, and 
hyperlipidemia 
4
. The result of the Diabetes Control and 
Complication Trials 
8
 and the United Kingdom 
Prospective Diabetes study 
8,9
 The critical issues for 
managing of diabetes are patient's adherence to exacting 
dietary, exercise, self care actions, and medication 
regimens. The greater the number of medications, the 
more drug related problems such as adverse drug 
reaction, drug interaction, medication non-adherence, no 
valid medical indication, and so on.
 8,9
  Poor medication 
adherence seems to be a significant barrier to the 
accomplishment of positive clinical outcomes among 
type 2 diabetes patients in both developed and 
developing countries.
9
 Increased pharmaceutical 
compliance was associated with fewer emergency 
department visit and patient admissions. Increased 
medication adherence was associated with decreased 
medical care cost.
10
 in recent years; pharmacists in many 
practice settings have begun providing patient centered 
services with the goal of improving drug therapy 
outcomes through practices such as pharmaceutical care. 
These PC programs have been found useful in 
improving the quality of care of patients with various 
diseases. Pharmacist's interventions in diabetes have 
also resulted in beneficial outcomes.
11, 12, 15
 This study 
intended to address this gap. Diabetes is a disease that 
needs more pharmacist involvement. Pharmacists 
possibly will contribute to such programs through 
pharmaceutical care. This Pharmaceutical care study 
will improve the quality of life,health-related quality of 
life. Pharmaceutical care decreases the fasting plasma 
glucose, Glycosylated hemoglobin (HbA1c) and Body 
mass index (BMI). Pharmaceutical care is the straight, 
responsible situation of medication-related care with the 
purpose of achieving definite outcomes that improve a 
patient's quality of life in Type 2 Diabetes mellitus. The 
generally Pharmaceutical care program improves 
patients’ outcomes, reduce cost, and promote patients 
quality of life.  
MATERIALS & METHODS 
Study design:  
The study was a prospective, open label and randomized 
control. It was conducted at SBHGM College, Civil 
hospital in Dhule Maharashtra. In this study, patients 
were divided into two groups by simple randomization 
technique; the first group is control group who only 
received only medical care, while the second one is 
intervention group, who received pharmaceutical care. 
The intervention group was followed up for 3 visits. The 
interval between each visit ranged from 8-9 weeks with 
for the follow up. Data Collection: The following data 
of each patient were recorded in the patient data 
collection forms (Patient Proforma). 
Study population:  
A total of 200 Type 2 diabetic patients were enrolled in 
the study, on the basis of inclusion & exclusion criteria 
after getting approval from Institutional Human Ethics 
Committee of SBHGM College. Civil hospital in Dhule 
Maharashtra. Patients were included into to the study if 
Patients with type 2 diabetes mellitus of either sex, 
Patients with age more than 38 yrs, Patients with HbA1c 
more than 7.5% and Patients with blood sugar level 
more than 140 mg / dl. Patients were excluded from the 
study if Patient with end stage kidney disease, Patient 
with heart failure, with chronic Diabetes problem and 
orthopedic problem, pregnant women with type 2 
diabetes. 
Ethical Consideration  
The protocol of study approved from Institutional 
Human ethical Committee of SBHMG civil hospital 
Dhule Maharashtra. clearance was obtained from the 
Ethical Committee. The study aim & objectives were 
explained to the patients and informed written consent 
was obtained in local language from them before the 
data collection. 
Study materials:  
Patient data collection Form  
“As per standard guidelines, Patient data collection 
Form was set and got approval from diabetologist for 
composed patient data and Pharmaceutical care issues”. 
The form which contain demographic data like Name, 
file number, weight, height, address, telephone number  
age, sex, social history, Medical Data Family history of 
diabetes, food or drug allergies, past medical history, 
past medication history, hypertension and hyper-
lipidemia , current treatment regimen, change of 
prescription drugs and current status of blood glucose 
level. 
Clinical outcome data Fasting plasma glucose (FPG), 
glycated hemoglobin (HbA1c), Body mass index 
(kg/m
2
).
               
 
Process evaluation data Drug therapy problems and 
adherence by pill count and Morisky-Green test that 
consists of the following questions.
18ʻʻ
Do you ever 
forget to get your medicine, “Are you careless at times 
about taking your medicine, “When you experience 
better, do you sometimes stop taking your medicine, 
Sometimes if you feel worse when you take the 
medicine, do you stop taking it.  
Data and statistical analysis  
The data were entered into a Microsoft Excel 
Spreadsheet, after data cleanout the data were 
transported into SPSS.Statistical Package for the Social 
Sciences-version 1.6 package software program for 
statistical analysis.
13
Descriptive statistics (numbers and 
percentage) were calculated for all variables, as well as 
analytical statistics was done to find the relations 
between variables.  
RESULTS 
A total 223 patients were involved in the study out of 
which 23 patients didn’t complete study Out of 223 
patients, these patients were distributed into different 
two such as control group I (n-100) without 
pharmaceutical care program and Pharmaceutical care 
program (intervention) groupII (n-100). there were 200 
patients who completed the study. The other 23patients 
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were excluded because they came too late after first or 
second visits. All patients were counseled after the 
selection into the study regarding Disease information, 
medication, diet, exercise and personal hygiene and 
motivate to improve life style modification. All patients 
baseline parameter were recorded before the 
pharmaceutical care program counseling as control 
values and recorded at each follow up. Demographic 
characteristics of patients As Shown in Table 1. 
 
Table 1: Demographic characteristics of patients 
Parameter Control Group-I (N=100) Pharmaceutical care GroupII (N=100) 
Sex :Male/ Female 63/37                                                         60/40 
Age(yrs) 
40-49 
50-59 
≥60  
Mean ±S.D.  
 
13(13%) 
43(43%) 
44(44%) 
56.53±5.96 
 
12(12%) 
49(49%) 
39(39%) 
56.87±6.72 
Diabetes duration (yrs) 
0-5 
≥ 6 
Mean ±S.D. 
 
83(83%) 
17(17%) 
4.12±2.09 
 
71(71%) 
29(29%) 
5.06±1.92 
BMI (Kg/m
2 
) 26±2.9 26± 3.1 
Family history of DM 
 Yes 
 No 
 
52(52%) 
48(48%) 
 
49(49%) 
51(51%) 
Hypertension. 
Normal 
Hypertensive  
 
57(57%) 
43(43%) 
 
53(53%) 
47(47%) 
 
Effect of pharmaceutical care program on 
fasting plasma glucose level (FPG) (Given in Table 
No.2): 
The baseline value of FPG of Group-I was 213.6± 
42.87and it no reduced significantly 220.0± 43.18after 6 
month. The baseline value of FPG Group-II of was 201 
± 41.40 and it reduced significantly upto 160± 0.8after 6 
month.. There were statistical significant differences in 
FPG found only in intervention Group- II. P-value < 
0.05 considered as statistical significant differences. 
Shown in Table No 2. 
Effect of pharmaceutical care program on 
glycosylated hemoglobin: (Given in Table No. 2) 
The statistical significant difference reductions in the 
glycosylated hemoglobin level were observed among in 
intervention Group- II. The HbA1c was found to be 
reduced more significantly in group II patients from 
9.41 ± 1.06 to 8.23 ± 0.85. P-value < 0.05 considered as 
statistical significant differences .shown in Table No 2. 
 Effect of pharmaceutical care program on 
BMI: (Given in Table No. 2) 
The baseline values of BMI of G-I and Group-II were 
26±2.9, 26± 3.1 after 6 month final values  BMI of G-I 
and Group-II were 26 ± 2.9, 24 ± 1.8 There were 
statistical significant differences in BMI found only in 
intervention Group- II. P-value < 0.05 considered as 
statistical significant differences shown in Table No 2. 
 
 Table 2: Comparative analysis of baseline and final values between patients in the Pharmaceutical care 
program and control groups. 
Parameter          Control group N=(100) 
 
Baseline Values        Final Values 
 PC Intervention group N=(100) 
 
Baseline Values      Final Values 
FPG(mg/dl) 213.6± 42.87               220.0± 43.18 201 ± 41.40              160.8± 26.43 
HbA1c (%) 9.38 ± 1.4                    9.62 ± 1.35 9.41 ± 1.06               8.23 ± 0.85 
BMI(kg/m2) 26±2.9                         26 ± 2.9 26± 3.1                     24 ± 1.8 
P value 0.197                            0.001 0.341                          0.000 
Values are expressed as Mean ± SD (n=100 for each group)            P-value < 0.05 considered as statistical significant differences 
 
Medication Adherence There are many methods for the 
assessment of medication compliance. In this study, 
indirect methods have been used (interview and pill 
count technique) for the evaluation of Adherence among 
patients in the intervention group. Medication 
Adherence from the first visit until the end of the study 
is summary in Table 3. 
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Table 3: Mean adherence change at each visit for intervention group. 
Adherence change                             Visiting time 
First visit N (%)          Second visit N(%)        Third visit N (%) 
P value 
NonAdherence    49(77.4)                     28(41.9)                          15(19.0) 0.000 
 
Adherence    14(22.6)                     39(58.1)                          51(81.0) 
  
0.000 
 
There is an improvement in the Medication Adherence 
which is statistically significant (p value < 0.05). 
Drug Therapy Problems: Drug therapy problems 
(DTPs) were identified in the intervention group during 
the study. It is discussed in literature review 16. DTPs 
are classified into 7 categories. In order to identify and 
resolve DTPs 7 points are considered among patients in 
the intervention group that include the followings. 
Unnecessary drug therapy, needs addition drug therapy, 
Dosage too low, Dosage too high, Drug therapy 
ineffective, adverse drug reaction, and Non adherence.  
At the first visit, 25 patients have one DTP, 17 patients 
have two DTPs, and 5 patients have three DTPs, at the 
second visit two DTPs were identified among three 
patients and at the third visit just one DTP is found in 
one patient, considerable resolving and prevention of 
DTPs have been found that is statistically significant (P- 
value less than 0.05). 
 
Table 4: Mean Drug therapy problems (DTPs) for the intervention group during the study. 
DTP options                                        Visiting time  P value  
 
 No DTP 
One DTP 
Two DTP 
Three DTP 
First visit N (%)              Second visit N (%)                  Third visit N (%)  
23(33.9)                            61(95.2)                                     63(98.4)     
25(37.1)                            3(4.8)                                         1(1.6) 
17(24.2)                            0(0.0)                                         0(0.0) 
5(4.8)                                0(0.0)                                         0(0.0) 
 
 
0.000 
 
 
DISCUSSION 
Pharmacist is main part in a health care team. This team 
normally consists of pharmacist, physician, nurse, 
technician, and other health care professions. All of the 
members in health care team have important roles in 
diabetes management in accomplishing the goal of 
treatment, improving quality of life, controlling disease 
and its complications, detaining complication, and 
decreasing mortality and morbidity.
1,4,5
 In this present 
study pharmacist is main role in pharmaceutical care 
program   Pharmacists’ interventions are an important 
factor to improve glycemic control in diabetic type2 
patients. Pharmacists’ interventions include diabetes 
education and counseling on disease, drug, diet, 
exercise, life style modification, and self management, 
identifying and solving drug-related problems, 
improving glycemic control, more recent studies, all 
these interventions used in present study. HbA1c levels, 
Fasting Blood Glucose levels and Body Mass Index 
values significantly reduced with pharmacists’ 
interventions compared with usual care.
14
 Mean 
difference in the change of HbA1c, FPG and BMI This 
would help patients meeting the target of their treatment. 
In This present study significant fall in the values of 
HbA1c, FPG and BMI in the intervention group II as 
compared to control groupI.differences is 1.18±0.75, 
41±14.97, & 2.13 respectively. The data analysis 
showed there were significant reductions in FPG, 
HbA1c, and BMI (160± 0.8mg/dl, 8.23 ± 0.85%.and 24 
± 1.8kg/m
2
respectively) obtained in the intervention 
group at the end of the study period. But there is no 
significant FPG, HbA1c, and BMI reduction in the 
control group. Our result complied with those of other 
similar studies. 
13
 The pharmacist's interventions in 
more recent studies also resulted in beneficial outcomes. 
In the study 
14,15
 studied the quality of care of a 
pharmacist-managed diabetes clinic. This inconsistent 
result could be explained by various reasons, for 
example: noncompliance to dietary control and exercise 
might explain this result.
15 
reported that poor 
compliance to dietary recommendations, missed 
appointment, and medication noncompliance were 
found in 56.69%, 13.33% and 5.55% of patients, 
respectively vast numbers of the diabetic patients suffer 
from poor dietary control. these may suggest that 
diabetic patients may need dietary modification 
specialists to assist them.
18
 The present study shows that 
better pharmacist education sessions, pill count, use of 
dietary chart and follow up calls and activities prove 
beneficial in falling mean FPG and HbA1cs 
significantly. To our knowledge, this type of 
intervention is first of its kind to be reported in Dhule 
Maharashtra region and shows that pharmacists could 
have added significance in “diabetes care management” 
through pharmaceutical care program. 
Medication Adherence: Medication Adherence was 
assessed in this study by direct methods, which include: 
question method and pill count method. In the first visit 
49 (77.4%) patients were non-adherence by question 
(Morisky-Green test). According to the protocol of the 
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Morisky-Green test, patients are considered Adherence 
to the treatment when they get a maximum score of four 
points, and non-adherence when they get three points or 
less 21. At the second visit, the number of non-
adherence patients was reduced to 28(41.9%) patients by 
using Morisky-Green test and pill count technique. For 
the pill count technique, the percentage of each 
antidiabetic medication compliance was calculated for 
each patient; then the average percentage of all 
mediaction adherence was calculated, according to 
Sackett D.L if the result is more than or equal to 80% 
the patient is considered adherence.
18
 At the third visit, 
compliance rate was assessed by Morisky-Green test 
and pill count technique, the number of non-adherence 
patients was reduced to 15(19%) patients.
17,18
 Our 
results show that the major cause of non-adherence is 
forgetting to take medications (at the end of the study), 
the reasons of forgetting to take medications were 
mainly due to forgetfulness, being too busy, hard 
working and uneducated.These causes may be solved if 
patients educate the importance of taking medicine at 
correct time and punctuality. This study disclosed that, 
the pharmacist may play an important role to teach 
patients about diabetic drugs and disease, to reduce the 
rate of non-adherence among diabetic patients. 
Drug Therapy Problems: Drug therapy problems (DTPs) 
were adapted from the definition of Cipolle and strand 
and it was classified into four categories indication, 
efficacy, safety and non-adherence.
5,10
 
In this study, the non-adherence problems were the 
highest among DTPs. During the 2nd and 3rd visits for 
the intervention group, the intervention was accepted 
and the DTPs was solved in 98 cases (231 cases of DTP 
were not solved) and DTPs was solved in 17 cases (13 
cases of DTP were not solved), respectively.  
CONCLUSION 
In this study result showed that there are significant 
reductions in glycemic levels i.e. FPG, HbA1C and BMI 
for the intervention group this result recommended that, 
the implementation of the pharmaceutical care program 
might result in good Glycemic control compared to 
usual medical care. In term of medication adherence, 
this study showed that, pharmaceutical care program can 
increase the rate of medication adherence among 
patients in the intervention group. Drug therapy problem 
is also one of the important objectives for this study, the 
study findings showed that the numbers of patients who 
do not have any DTPs from the 1st visit to the 3rd are 
significantly improved. In This present study we 
conclude that Pharmaceutical care program study will 
improve the quality of life, “health-related quality of 
life”. The study, therefore, recommended that the 
pharmaceutical care program on the total care of the 
patients should be established in all chronic disease. The 
Pharmaceutical Care provided by the pharmacist to the 
type 2 diabetic patients was effective in reducing the 
blood glucose levels and in improving their overall 
quality of life. 
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